KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-

Derek N. Bremmer; Cornelius J. Clancy; Ellen G. Press; Reem Almaghrabi; Liang Chen; E. Yohei Doi; M. Hong Nguyen; Ryan K. Shieldsb

doi:10.1128/AAC.03831-14

KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-

Derek N. Bremmer
, Cornelius J. Clancy
, Ellen G. Press
, Reem Almaghrabi
, Liang Chen
, E. Yohei Doi
, M. Hong Nguyen
, Ryan K. Shieldsb

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

20 被引用数 (Scopus)

抄録

The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1× and 4×the MIC) was bactericidal against 30% and 85% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90% of the strains, indicating that the combination may overcome resistance.

本文言語	英語
ページ（範囲）	7597-7600
ページ数	4
ジャーナル	Antimicrobial agents and chemotherapy
巻	58
号	12
DOI	https://doi.org/10.1128/AAC.03831-14
出版ステータス	出版済み - 01-12-2014
外部発表	はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

薬理学
薬理学（医学）
感染症

文献へのアクセス

10.1128/AAC.03831-14

他のファイルとリンク

引用スタイル

@article{fdf37b443c2e4cb69de5f65989199e03,

title = "KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-",

abstract = "The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1{\texttimes} and 4{\texttimes}the MIC) was bactericidal against 30\% and 85\% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90\% of the strains, indicating that the combination may overcome resistance.",

author = "Bremmer, \{Derek N.\} and Clancy, \{Cornelius J.\} and Press, \{Ellen G.\} and Reem Almaghrabi and Liang Chen and Doi, \{E. Yohei\} and Nguyen, \{M. Hong\} and Shieldsb, \{Ryan K.\}",

note = "Publisher Copyright: {\textcopyright} 2014 American Society for Microbiology. All Rights Reserved. This project was supported by the National Institutes of Health through grant no. KL2TR000146 awarded to R.K.S. and by the University of Pittsburgh Medical Center XDR Pathogen Laboratory.",

year = "2014",

month = dec,

day = "1",

doi = "10.1128/AAC.03831-14",

language = "English",

volume = "58",

pages = "7597--7600",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "12",

}

TY - JOUR

T1 - KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-

AU - Bremmer, Derek N.

AU - Clancy, Cornelius J.

AU - Press, Ellen G.

AU - Almaghrabi, Reem

AU - Chen, Liang

AU - Doi, E. Yohei

AU - Nguyen, M. Hong

AU - Shieldsb, Ryan K.

N1 - Publisher Copyright: © 2014 American Society for Microbiology. All Rights Reserved. This project was supported by the National Institutes of Health through grant no. KL2TR000146 awarded to R.K.S. and by the University of Pittsburgh Medical Center XDR Pathogen Laboratory.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1× and 4×the MIC) was bactericidal against 30% and 85% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90% of the strains, indicating that the combination may overcome resistance.

AB - The aminoglycoside-modifying enzyme AAC(6')-Ib is common among carbapenem-resistant Klebsiella pneumoniae (CR-Kp) strains. We investigated amikacin (AMK) activity against 20 AAC(6')-Ib-producing CR-Kp strains. MICs clustered at 16 to 32 μg/ml. By the time-kill study, AMK (1× and 4×the MIC) was bactericidal against 30% and 85% of the strains, respectively. At achievable human serum concentrations, however, the majority of strains showed regrowth, suggesting that AAC(6')-Ib confers intermediate AMK resistance. AMK and trimethoprim-sulfamethoxazole (TMP-SMX) were synergistic against 90% of the strains, indicating that the combination may overcome resistance.

UR - https://www.scopus.com/pages/publications/84912101206

UR - https://www.scopus.com/pages/publications/84912101206#tab=citedBy

U2 - 10.1128/AAC.03831-14

DO - 10.1128/AAC.03831-14

M3 - Article

C2 - 25288089

AN - SCOPUS:84912101206

SN - 0066-4804

VL - 58

SP - 7597

EP - 7600

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 12

ER -

KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-

抄録

UN SDG

All Science Journal Classification (ASJC) codes

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル